S3 Diabetic complications 1 : What’s new in diabetic microvascular complications?
Friday 29 September 09:00~11:00 | Place: Convention Hall C
Chairman: Dong-Seop Choi, Kyung Soo Ko
    • S3 Diabetic complications 1 : What’s new in diabetic microvascular complications? In this session, the four prominent professors will present their research in the field of diabetic microvascular complications. Prof. Niewczas from the Joslin Diabetes Center will talk about her translational studies using metabolomics and proteomics high throughput platforms to search for determinants of chronic diabetic complications. Prof. Chul-Woo Yang from Catholic university will present his recent research to show the beneficial effects of empagliflozin on pancreatic islet dysfunction and renal injury in experimental model of tacrolimus-induced DM. Third, prof. Seung−Hyun Ko from Catholic university will give a lecture about the clinical implication of cardiovascular autonomic neuropathy as a risk factor for cardiovascular disease and mortality including her recent publication. Lastly, prof. Nam Hoon Kim from Korea University will deliver a novel safety issue, with respect to diabetic retinopathy, that had been suggested by preclinical and clinical data of DPP-4 inhibitors. From these lectures, we hope you can get several novel concepts in diabetic microvascular complications.
Chul Woo Yang The Catholic University of Korea, Korea S3-1 SGLT2 inhibitor has renal protective effect?
Monika Niewczas Harvard University, USA S3-2 Upcoming new targets for diabetic kidney disease
Seung-Hyun Ko The Catholic University of Korea, Korea S3-3 Cardiovascular autonomic neuropathy and cardiovascular outcomes in type 2 diabetes
Nam Hoon Kim Korea University, Korea S3-4 DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug
S8 Diabetic complications 2 : Novel targets and therapies of diabetic cardiovascular disease
Friday 29 September 16:00~18:00| Place: Convention Hall C
Chairman: In Joo Kim, Minho Shong
    • Novel targets and therapies of diabetic cardiovascular disease Diabetes dramatically increases the risk of various cardiovascular complications, including retinopathy, coronary artery disease, and stroke. In this session, four prominent researchers will give lectures about novel targets and therapies of diabetic cardiovascular disease. Professor Jeong Hun Kim, from Seoul National University, will present recent experimental results of therapeutic applications such as small peptide, small molecule as well as nanoparticles beyond anti-VEGF antibody. In addition, some results of in vivo genome editing with Cas9 RNPs in vision-threatening retinopathy would be provided. Dr. Do Young Park, from Sungkyunkwan University, will focus on the crucial role of pericyte for blood-retinal barrier buildup during development of diabetic retinopathy. Dr. Brian Wong, from Vesalius Research Center in Belgium, will present how endothelial cells change their metabolism during vascular branching and the therapeutic potential of targeting endothelial metabolism for anti-angiogenic strategies. Professor Jae-Kwan Song, from University of Ulsan, will deliver a lecture on previously unidentified roles of dipeptidyl pedtidase-4 (DPP-4) and insulin-like growth factor-1 as key proteins of valvular calcification process and crucial targets for protecting calcific aortic valve disease development.
Jeong Hun Kim Seoul National University, Korea S8-1 Translational research on vaso-proliferative retinopathy using in vivo genome editing
Do Young Park Sungkyunkwan University, Korea S8-2 Plastic roles of pericytes in the blood-retinal barrier
Brian Wong Washington University, USA S8-3 Metabolic regulation of lymphatic development and lymphangiogenesis
Jae-Kwan Song University of Ulsan, Korea S8-4 Aortic valvular calcification and DPP4 inhibitors
Quick Menu
On-line submission